The trajectory of companies tied to Viagra's past presents a intricate investment scenario . While the initial success generated substantial gains, generic copies have significantly eroded revenue. Investing in related pharmaceutical companies now requires a careful assessment of patent protection , evolving healthcare trends , and the potential fo